BioSpace News Archive

Amber Therapeutics (‘Amber’ or the ‘Company’), an innovative medical technology company developing next-generation, intelligent bioelectrical therapies to transform clinical outcomes in patients with functional disorders of the peripheral nervous system, announces the presentation of the first data from its AURA-2 (Augmenting Urinary Reflex Activity) first-in-human study evaluating Amber-UI.

Scilex Holding Company announced acceptance of an abstract for poster and oral presentation at the 2024 Annual Meeting of the American Academy of Pain Medicine which will take place on March 7-10, 2024 in Scottsdale, Arizona.

Mabwell (688062.SH) announces that its self-developed novel ADC drug targeting Nectin-4 (R&D Code: 9MW2821) has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma (hereinafter referred to as “ESCC”).

Curadev, a drug discovery and development company, announced today a significant milestone in its development of drugs targeting the immune system to treat cancer.

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that Avidity management will be participating at the following upcoming conferences.

CorNeat Vision, a leader in innovative medical device solutions, proudly introduces the CorNeat EverPatch, a pioneering synthetic tissue-integrating matrix designed to revolutionize ophthalmic surgeries.

Ginkgo Bioworks has announced the signing of an agreement with Qatar Free Zones Authority and Doha Venture Capital to build the first Center for Unified Biosecurity Excellence in Doha within Qatar Free Zones.

Prolocor, Inc., a healthcare startup developing an innovative precision diagnostic test with the potential to predict the risk of thrombosis by quantifying FcγRIIa, announced that they have successfully raised $1.7 million in bridge financing.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced a research collaboration with the National Cancer Center Hospital East in Japan to study the prognostic and predictive value of molecular residual disease testing.

Roshal Health, a new leader providing hospital grade, on-site, and on-demand ultrasound and echocardiogram services to ERs, micro-hospitals, rural hospitals, and hospital offsite facilities, announced that it secured $10 million in financing.